Dexmethylphenidate - Celgene/Novartis

Drug Profile

Dexmethylphenidate - Celgene/Novartis

Alternative Names: d-methylphenidate; D-methylphenidate hydrochloride; D-MPH; Dexmethylphenidate; Dexmethylphenidate hydrochloride; Focalin; Focalin XR

Latest Information Update: 16 Nov 2015

Price : $50

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Novartis
  • Class Phenylacetates; Piperidines; Small molecules
  • Mechanism of Action Adrenergic receptor agonists; Central nervous system stimulants; Dopamine uptake inhibitors; Neurokinin 1 antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Attention-deficit hyperactivity disorder
  • Discontinued Fatigue

Most Recent Events

  • 05 Nov 2015 Par Pharmaceutical Inc has been acquired by Endo International
  • 18 Dec 2013 Elan Corporation has been acquired and merged into Perrigo
  • 15 Jul 2013 Novartis completes a phase III trial in Attention-deficit hyperactivity disorder in USA, Belgium, Colombia, Denmark, Germany, and Sweden (NCT01338818)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top